Based on Johnson & Johnson’s (JNJ) full-year 2024 financial results and Q3 2025 performance updates, the company operates through two primary segments following the spin-off of its consumer health business (Kenvue).
Revenue Ranking by Segment (Full-Year 2024)
| Business Segment | 2024 Revenue (USD) | % of Total Revenue | Key Growth Drivers |
| Innovative Medicine | $56.96 Billion | 64.1% | Darzalex, Stelara, Tremfya |
| MedTech | $31.86 Billion | 35.9% | Cardiovascular, Surgery |
| J&J Group | $88.82 Billion | 100% |
Based on the 2024 full-year financial results, here is the revenue list for Johnson & Johnson’s top 10 performing products and their respective share of total revenue ($88.82 billion):
Top 10 Product Revenue List (2024)
| Rank | Product Name (Indication) | 2024 Revenue (USD Billions) | % of Total Revenue | Growth (YoY) |
| 1 | Darzalex (Multiple Myeloma) | 11.67 | 13.1% | +20.0% |
| 2 | Stelara (Psoriasis/Crohn’s) | 10.42 | 11.7% | -5.1% |
| 3 | Tremfya (Plaque Psoriasis) | 3.98 | 4.5% | +26.3% |
| 4 | Imbruvica (Blood Cancers) | 3.02 | 3.4% | -7.2% |
| 5 | Invega Sustenna (Schizophrenia) | 2.95 | 3.3% | +0.4% |
| 6 | Erleada (Prostate Cancer) | 2.86 | 3.2% | +24.1% |
| 7 | Uptravi (Pulmonary Hypertension) | 1.65 | 1.9% | +11.2% |
| 8 | Xarelto (Anticoagulant) | 1.53 | 1.7% | -10.5% |
| 9 | Simponi (Arthritis) | 1.48 | 1.7% | -4.2% |
| 10 | Spravato (Depression) | 1.12 | 1.3% | +45.2% |
Key Financial Takeaways
- The New Leader: Darzalex has officially overtaken Stelara as J&J’s top-selling product. Its growth is primarily driven by the high adoption rate of the subcutaneous formulation (Faspro).
- The Patent Cliff: Stelara remains a top contributor but is experiencing a slight decline in revenue as it approaches patent expiration and faces biosimilar entry in 2025.
- Emerging Blockbusters: Spravato saw the highest percentage growth (+45.2%) in 2024, becoming a crucial pillar of J&J’s Neuroscience portfolio.
- MedTech Impact: While individual medical devices are not listed as “single products” like drugs, the Electrophysiology suite (under MedTech) generates over $5 billion annually, making it comparable to a top-tier pharmaceutical asset.
Within Johnson & Johnson’s MedTech department, the highest revenue contributors are concentrated in Electrophysiology, Vision Care, and specialized surgical tools. Based on 2024 results and 2025 performance data, here are the top-grossing medical device product lines:
Top-Grossing Medical Device Product Lines (2024)
| Rank | Product Line / Brand | Segment | Est. 2024 Revenue (USD Billions) | % of MedTech Revenue | Key Feature |
| 1 | Biosense Webster (Electrophysiology) | Cardiovascular | 5.27 | 16.5% | Leading cardiac ablation catheters for arrhythmia. |
| 2 | Acuvue (Contact Lenses) | Vision | 3.73 | 11.7% | Global market leader in daily and reusable lenses. |
| 3 | DePuy Synthes Trauma | Orthopaedics | 3.05 | 9.6% | Plates, screws, and nails for fracture repair. |
| 4 | Ethicon Wound Closure | Surgery | 2.50+ | 8.0%+ | Dominant market share in sutures and staplers. |
| 5 | Abiomed Impella | Cardiovascular | 1.50 | 4.7% | World’s smallest heart pumps for recovery. |
Segment Insights and Strategic Shifts
1. Cardiovascular: The Growth Engine
The Electrophysiology suite (Biosense Webster) is J&J’s most successful medical technology asset. Following the $13.1 billion acquisition of Shockwave Medical in 2024, J&J has solidified its position in the interventional cardiovascular space. This segment is expected to be the primary profit driver for MedTech in 2025-2026.
2. Surgery: Advanced Instrumentation
Ethicon is a foundational brand for J&J. While “Wound Closure” is the largest individual sub-category, the Advanced Surgery unit (which includes energy-based sealing tools and endocutters) generates nearly $4.5 billion collectively, serving as a critical component of modern operating rooms.
3. Orthopaedics: Specialization
While the Orthopaedics segment is large ($9.16 billion total), it is highly fragmented. J&J is currently undergoing a two-year restructuring of DePuy Synthes to exit lower-margin product lines and focus on high-growth areas like robotic-assisted knee and hip replacements (VELYS system).
4. Vision: Reliable Cash Flow
Acuvue remains the world’s #1 contact lens brand. Despite being more consumer-facing than a surgical implant, it provides a highly stable recurring revenue stream that helps fund R&D for more volatile MedTech surgical sectors.
Johnson & Johnson’s top two pharmaceutical products, Darzalex and Stelara, represent two different stages of a drug’s lifecycle. While Darzalex is a growing market leader, Stelara is currently fighting to maintain its position against lower-cost competitors.
1. Darzalex (Daratumumab) — The Growth Engine
Darzalex is a biologic used primarily for Multiple Myeloma. In 2024, it reached 11.67 billion in sales, growing 20% year-over-year.
- Competitive Landscape:
- Direct Competitor: Sanofi’s Sarclisa (isatuximab) is the primary rival. Both target the CD38 protein. However, Darzalex maintains over 80% market share due to its “First-mover” advantage and extensive data for “Front-line” therapy (use in newly diagnosed patients).
- Indirect Competitors: Newer CAR-T cell therapies (like BMS’s Abecma) and Bispecific antibodies (like J&J’s own Tecvayli) are emerging for late-stage patients.
- Key Advantage: J&J successfully shifted the market to Darzalex Faspro (a subcutaneous injection). This reduced administration time from hours to just 3–5 minutes, creating a massive barrier for competitors who only offer intravenous (IV) versions.
2. Stelara (Ustekinumab) — The Patent Cliff
Stelara is used for Psoriasis, Crohn’s Disease, and Ulcerative Colitis. It generated 10.42 billion in 2024 but has entered a period of revenue decline.
- Competitive Landscape:
- The Biosimilar Threat: As of early 2025, biosimilars (generic versions of biologics) have hit the market. Amgen’s Wezlana was the first to launch in the US, followed by versions from Sandoz and Samsung Bioepis. These products are typically priced 30% to 50% lower than Stelara.
- Next-Generation Rivals: AbbVie’s Skyrizi and Rinvoq are Stelara’s most dangerous clinical competitors. Clinical trials have shown that Skyrizi often achieves higher rates of “clear skin” in psoriasis patients, leading many doctors to switch new patients away from Stelara.
- J&J’s Strategy: To offset Stelara’s losses, J&J is aggressively migrating patients to Tremfya, their newer immunology drug which has better long-term data and stronger patent protection.
Comparison Summary
| Feature | Darzalex | Stelara |
| Market Status | Expanding Leader | Defensive / Declining |
| Primary Rival | Sanofi (Sarclisa) | Amgen (Wezlana), AbbVie (Skyrizi) |
| Main Challenge | Maintaining dominance in 1st-line treatment | Patent expiration & Biosimilar entry |
| Future Outlook | Continued growth through 2028+ | Significant revenue erosion expected in 2025/2026 |
In terms of technology, J&J’s Darzalex and Sanofi’s Sarclisa both target the CD38 protein, but they differ significantly in their binding epitopes, mechanisms of action (MoA), delivery platforms, and clinical reach.
1. Fine Nuances in Mechanism of Action (MoA)
While both are anti-CD38 monoclonal antibodies, they bind to different “epitopes” (specific locations on the protein), leading to distinct biological effects:
- Darzalex (Daratumumab): Strongest in Immune-Mediated Killing.
- CDC (Complement-Dependent Cytotoxicity): Darzalex is highly potent at activating the complement system to punch holes in cancer cell membranes.
- Immunomodulation: It expands helper and cytotoxic T cells while increasing T-cell clonality, essentially “tuning” the immune system to fight the tumor more effectively.
- Sarclisa (Isatuximab): Strongest in Direct Apoptosis Induction.
- Direct Killing: Unlike Darzalex, Sarclisa can trigger cancer cell “suicide” (apoptosis) directly without needing the help of other immune cells (like NK cells).
- Enzymatic Inhibition: It is a more potent inhibitor of the CD38 ectoenzyme, which reduces the production of immunosuppressive molecules (like adenosine), thereby making the tumor microenvironment less “shielded” from the immune system.
2. Delivery Technology: The “Convenience” War
This is J&J’s primary competitive moat. The technology used to deliver the drug under the skin (subcutaneous) determines patient preference and clinic efficiency.
| Feature | Darzalex Faspro | Sarclisa SC (2025 Data) |
| Delivery System | Halozyme ENHANZE® Technology | Enable Injections On-body Injector |
| Key Ingredient | Hyaluronidase (rHuPH20) | Hyaluronidase-free |
| Admin Time | ~3-5 minutes (Manual Push) | ~10-15 minutes (Hands-free device) |
| Mechanism | Temporarily degrades subcutaneous tissue to allow rapid absorption of high volumes. | Uses an automated pump to slowly push the volume into the skin. |
| Advantage | Extremely fast; no wearable device needed; high clinic throughput. | Very low systemic reaction rate (1.5%); preferred by patients wanting hands-free. |
3. Clinical Trial Data & Efficacy (2024-2025)
J&J has leveraged its five-year head start to expand Darzalex into all stages of the disease, from pre-cancer to late-stage relapse.
- Front-line Dominance (PERSEUS & MAIA Trials): Darzalex (D-VRd) achieved a 75% MRD negativity rate (no detectable cancer cells at a $10^{-5}$ sensitivity level), setting a high bar for any competitor.
- Disease Interception (Smoldering Myeloma): On November 6, 2025, the FDA approved Darzalex Faspro as the first and only treatment for high-risk smoldering multiple myeloma (AQUILA trial). This allows J&J to treat patients before they develop active cancer, a market Sanofi has yet to enter.
- Relapsed Efficacy (ASH 2025): New data for Darzalex + Tecvayli (a bispecific antibody) showed a 54% reduction in the risk of death compared to standard therapies, reinforcing Darzalex as the “backbone” of modern combinations.
4. Technical Summary: Who Has the Edge?
- Darzalex’s Edge: Its ENHANZE® technology provides unmatched speed and convenience for clinics. Clinically, its dominance in First-line (NDMM) and Smoldering Myeloma (SMM) ensures that most patients start their treatment journey with a J&J product.
- Sarclisa’s Challenge: While technically superior in inducing direct cell death and showing promising safety data with its new On-body Injector (OBI) in 2025, Sarclisa still lags behind in total indications and clinical “real estate.” It is currently positioned more as a powerful alternative for relapsed patients or those with high-risk genetic profiles.
In Johnson & Johnson’s (J&J) MedTech division, the highest revenue contributors are Biosense Webster (Cardiovascular/Electrophysiology) and Acuvue (Vision Care). As of 2025 and heading into 2026, these products face fierce competition from technological shifts and market rivals.
1. Biosense Webster (Electrophysiology)
This is the “crown jewel” of MedTech, generating over $5.3 billion in 2024 and continuing to lead growth in 2025.
- Technological Moat: J&J’s CARTO 3 mapping system is the industry standard. In late 2024, J&J received FDA approval for the VARIPULSE platform, their entry into the Pulsed Field Ablation (PFA) market, which is safer and faster than traditional thermal ablation.
- Key Competitors:
- Boston Scientific: Their Farapulse PFA system is the primary rival, having gained massive market share in 2024 due to its ease of use.
- Medtronic: Competes with the PulseSelect PFA system. Medtronic leverages its massive hospital network to bundle cardiac products.
- 2025-2026 Outlook: The battle has shifted to “PFA 2.0.” J&J is integrating PFA with its dominant mapping software to offer a “complete package” that rivals struggle to match in precision.
2. Acuvue (Vision Care / Contact Lenses)
Vision Care is the second-largest MedTech pillar, led by the Acuvue Oasys and 1-Day franchises.
- Technological Moat: J&J focuses on material science, such as the HydraLuxe and TearStable technologies in the Acuvue Oasys MAX 1-Day. Recent 2025 data shows these lenses outperform competitors in “end-of-day comfort” for digital device users.
- Key Competitors:
- Alcon: The Dailies Total1 and Precision1 series are the most direct clinical rivals, often preferred for their “water gradient” technology.
- CooperVision: Dominates the specialty lens market (e.g., MiSight for myopia management) and offers aggressive pricing on high-volume silicone hydrogel lenses.
- 2025-2026 Outlook: J&J is pivoting toward “Functional Vision,” launching specialized lenses for astigmatism and multifocal needs (Oasys MAX 1-Day Multifocal) to defend high-margin segments from Alcon.
MedTech Strategic Competition Summary (2025)
| Category | Leading J&J Brand | Primary Rival(s) | 2025 Competition Focus |
| Electrophysiology | Biosense Webster | Boston Scientific, Medtronic | PFA (Pulsed Field Ablation) adoption and 3D mapping integration. |
| Vision Care | Acuvue | Alcon, CooperVision | Material comfort for “digital eyes” and high-growth multifocal lenses. |
| Cardiovascular | Shockwave / Abiomed | Abbott, Boston Scientific | Intravascular lithotripsy (IVL) and heart recovery pumps. |
| Surgery | Ethicon | Medtronic, Intuitive Surgical | Transitioning from manual tools to the Ottava robotic platform. |
Future Pivot: The Ottava Platform
While Ethicon leads in sutures and traditional tools ($10B+ category), it faces a massive threat from Intuitive Surgical (Da Vinci). J&J’s Ottava surgical robot is currently in pivotal clinical trials (late 2025), with a planned de novo submission in 2026. This platform is critical for J&J to reclaim the “digital surgery” market.
Data Sources:
- J&J Q3 2025 Results & 2026 Outlook
- Electrophysiology Market Trends 2025 – Towards Healthcare
- J&J Vision Data on Acuvue Oasys MAX 1-Day vs Alcon (Oct 2025)